BNT113 misses PFS endpoint in head and neck cancer; overall-survival follow-up continues
Company / institutional announcement · BioNTech
Source published: · Event / reporting date: 2026-10-13
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
BioNTech reported that AHEAD-MERIT, a Phase 2/3 trial of BNT113 plus pembrolizumab, did not meet its progression-free survival dual primary endpoint versus pembrolizumab alone. The study enrolled patients with previously untreated, unresectable recurrent or metastatic HPV16-positive, PD-L1-expressing head and neck cancer. Overall-survival follow-up continues; under the prespecified design, a significant survival benefit could still establish a positive trial outcome.
Why it may matter
The readout highlights uncertainty for fixed-antigen mRNA cancer vaccines while preserving the distinction between a missed PFS endpoint and pending survival results.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections